Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6K | -9K | -10K | -536 | -11K |
| Operating Income | -3M | -2M | -2M | -2M | -916K |
| EBITDA | -3M | -2M | -2M | -3M | -905K |
| Net Income | -3M | -4M | -4M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.039
-2.50% today
1Y Change
-98.58%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sigyn Therapeutics, Inc. (SIGY) is a Healthcare stock with listed on OTC. The stock last traded around $0.04 and down 98.6% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +33.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +33.4%, free cash flow +36.9% with operating margin -32561.7% and ROIC 60.6%. Valuation already assumes a fairly strong business story at price/sales 13.6. Stock Foundry combines SIGY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SIGY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SIGY Max Drawdown
-99.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SIGY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.6M
+52.9% YoY
Free Cash Flow
-$840.6K
+53.4% YoY
Revenue Growth
+0.0%
EPS Growth
+33.4%
Gross Margin
26.4%
Net Margin
-55785.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6K | -9K | -10K | -536 | -11K |
| Operating Income | -3M | -2M | -2M | -2M | -916K |
| EBITDA | -3M | -2M | -2M | -3M | -905K |
| Net Income | -3M | -4M | -4M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12K | 12K | 8K | 341K | 84K |
| Total Assets | 214K | 322K | 333K | 710K | 694K |
| Total Liabilities | 5M | 4M | 2M | 975K | 595K |
| Shareholder Equity | -4M | -3M | -2M | -265K | 99K |
| Total Debt | 2M | 2M | 2M | 980K | 519K |
| Net Debt | 2M | 2M | 2M | 639K | 434K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
830K
+53.2% YoY
Capital Expenditures
11K
+63.1% YoY
Free Cash Flow
841K
+53.4% YoY
Key ratios
Gross Margin
26.4%
Operating Margin
-32561.7%
Net Margin
-55785.8%
ROE
62.1%
Debt / Equity
-0.48x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.